According to Zacks, “Strata Skin Sciences, Inc. is a medical technology company which focused on the dermatology market. Its products include the XTRAC laser(R) and VTRAC(R) excimer lamp systems for treatment of psoriasis, vitiligo and other skin conditions as well as the MelaFind (R) system used for identification and management of melanoma skin cancer. Strata Skin Sciences, Inc., formerly known as MELA Sciences, Inc., is based in Horsham, Pennsylvania. “
Several other research analysts have also commented on SSKN. Northland Securities restated a buy rating and issued a $7.00 price target on shares of STRATA Skin Sciences in a report on Tuesday, May 14th. HC Wainwright set a $5.00 price target on shares of STRATA Skin Sciences and gave the company a buy rating in a report on Monday, July 8th. Finally, ValuEngine lowered shares of STRATA Skin Sciences from a buy rating to a hold rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $4.92.
Large investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in STRATA Skin Sciences in the first quarter valued at approximately $39,000. Northern Trust Corp acquired a new stake in STRATA Skin Sciences in the fourth quarter valued at approximately $36,000. Creative Planning grew its position in STRATA Skin Sciences by 42.9% in the second quarter. Creative Planning now owns 50,000 shares of the medical device company’s stock valued at $125,000 after acquiring an additional 15,000 shares in the last quarter. Acadian Asset Management LLC grew its position in STRATA Skin Sciences by 35.2% in the second quarter. Acadian Asset Management LLC now owns 52,715 shares of the medical device company’s stock valued at $131,000 after acquiring an additional 13,716 shares in the last quarter. Finally, BlackRock Inc. grew its position in STRATA Skin Sciences by 33.5% in the second quarter. BlackRock Inc. now owns 82,972 shares of the medical device company’s stock valued at $207,000 after acquiring an additional 20,803 shares in the last quarter. 30.98% of the stock is owned by institutional investors.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
Read More: Coverage Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.